Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD)

How Semaglutide Helps with Non-Alcoholic Fatty Liver Disease (NAFLD)

Semaglutide mimics the GLP-1 hormone to reduce appetite and slow stomach emptying, leading to significant weight loss. For patients with non-alcoholic fatty liver disease (nafld), this weight loss translates to meaningful improvements in condition-specific outcomes.

GLP-1s reduce liver fat content and inflammation; semaglutide approved for NASH/MASH in 2024. The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly produces an average weight loss of 15% of body weight over 68 weeks, with additional benefits for metabolic health markers.

Clinical Evidence for Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease (NAFLD) affects 25% of global population; 80-90% of obese individuals. Research shows that GLP-1 medications like semaglutide address both the weight component and the underlying metabolic dysfunction associated with non-alcoholic fatty liver disease (nafld). Patients with this condition often see compounding benefits from weight loss, including improved energy, mobility, and overall quality of life.

Semaglutide Dosing for Non-Alcoholic Fatty Liver Disease (NAFLD)

Semaglutide is taken as a once-weekly subcutaneous injection. The standard titration starts at 0.25mg and gradually increases to the maintenance dose of 2.4mg over 16-20 weeks. Dosing is the same regardless of the indication — your provider will monitor your response and adjust timing as needed.

Cost of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD)

Compounded semaglutide costs $149-399/month through telehealth providers. Brand-name Wegovy costs $1,300+/month without insurance. Many patients with non-alcoholic fatty liver disease (nafld) have associated comorbidities that improve insurance coverage chances.